Since the BDNF Val66Met has no relationship with the rates of change in cognitive decline among healthy adults with low Aβ, it has been proposed that high Aβ levels coupled with Met66 carriage may be used as prognostic markers in the preclinical stage of AD [163]. The gene discussed is BDNF; the disease is Alzheimer disease.